Odronextamab

Phase 3

Regeneron Pharmaceuticals, Inc. (REGN)

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

No Catalysts Found

No catalyst events have been recorded for this drug yet.

Competitive Landscape

1 competitor in Diffuse Large B-cell Lymphoma (DLBCL)

EPZMTazemetostat

Phase 2

View Full Landscape

Drug Information

Target Indication

Diffuse Large B-cell Lymphoma (DLBCL)

Clinical Trial

NCT06091865

Last updated: 1/2/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Regulatory Approvals

EMA8/22/2024

Ordspono

Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (r/r FL) after two or more lines of systemic therapy. Ordspono as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) after two or more lines of systemic therapy.

OrphanConditional

View on EMA

Drug Science

Mechanism of action & safety profile

Developer

REGN

Regeneron Pharmaceuticals, Inc.

Pharmaceutical Preparations•North America•NASDAQ

Related Pipeline

AlirocumabPhase 3

Homozygous Familial Hypercholesterolemia

StatinPhase 3